Thus, despite GBM not exhibiting BRCAness19, our results suggest that PARPis alone can be used for the treatment of Myc-driven GBM and that the inhibition of both PARP and ATR is effective even in non-Myc-amplified GBM. The gene discussed is ATR; the disease is glioblastoma.